Five Australian Biotechs Advance Products To Late Stages
This article was originally published in PharmAsia News
Five Australian biotechs are in various advanced-stage trials for products they have developed. Avexa has entered into an agreement with Monogram Biosciences of the United States to test the Australian firm's drug candidates as it begins Phase III trials of its apricitabine drug to fight HIV. Also at the Phase II or III stage with product candidates are Bionomics, ChemGenex and Progen Pharmaceuticals. In addition, Clinuvel Pharmaceuticals gained orphan-drug designation for its CUV-1647 hormone treating sun-related cancer problems. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?